Nationwide Fund Advisors increased its stake in shares of Endologix Inc. (NASDAQ:ELGX) by 318.1% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 194,539 shares of the company’s stock after buying an additional 148,006 shares during the period. Nationwide Fund Advisors owned approximately 0.24% of Endologix worth $2,424,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of ELGX. BlackRock Institutional Trust Company N.A. boosted its position in shares of Endologix by 4.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,827,084 shares of the company’s stock valued at $15,274,000 after buying an additional 79,354 shares during the last quarter. NN Investment Partners Holdings N.V. bought a new position in shares of Endologix during the first quarter valued at about $662,000. AXA boosted its position in shares of Endologix by 52.4% in the first quarter. AXA now owns 585,437 shares of the company’s stock valued at $4,894,000 after buying an additional 201,395 shares during the last quarter. Altrinsic Global Advisors LLC boosted its position in shares of Endologix by 9.4% in the first quarter. Altrinsic Global Advisors LLC now owns 580,000 shares of the company’s stock valued at $4,849,000 after buying an additional 50,000 shares during the last quarter. Finally, Bogle Investment Management L P DE bought a new position in shares of Endologix during the first quarter valued at about $387,000.
Shares of Endologix Inc. (NASDAQ:ELGX) traded down 2.65% during trading on Tuesday, hitting $12.86. 91,664 shares of the stock were exchanged. The stock has a 50-day moving average of $12.54 and a 200 day moving average of $12.07. The stock’s market cap is $1.06 billion. Endologix Inc. has a 12-month low of $6.51 and a 12-month high of $14.50.
Endologix (NASDAQ:ELGX) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.07. The business earned $51 million during the quarter, compared to analyst estimates of $46.30 million. Endologix had a negative net margin of 82.39% and a negative return on equity of 41.88%. The business’s revenue was up 29.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.18) earnings per share. Equities analysts predict that Endologix Inc. will post ($0.74) earnings per share for the current fiscal year.
Several research analysts have recently issued reports on ELGX shares. Royal Bank Of Canada upped their target price on shares of Endologix from $15.00 to $17.00 and gave the company an “outperform” rating in a report on Monday, June 13th. Canaccord Genuity upgraded shares of Endologix from a “hold” rating to a “buy” rating and set a $15.50 target price for the company in a report on Monday, June 13th. Piper Jaffray Cos. restated an “overweight” rating and issued a $15.00 target price on shares of Endologix in a report on Monday, June 13th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $16.00 price target (up previously from $15.00) on shares of Endologix in a research note on Wednesday, July 6th. Finally, BMO Capital Markets upgraded shares of Endologix from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $11.50 to $16.00 in a research note on Thursday, July 7th. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $13.79.
In other Endologix news, VP Jose A. Lima sold 4,710 shares of Endologix stock in a transaction on Friday, August 19th. The shares were sold at an average price of $11.68, for a total value of $55,012.80. Following the completion of the transaction, the vice president now owns 42,594 shares of the company’s stock, valued at $497,497.92. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Michael V. Chobotov sold 14,000 shares of Endologix stock in a transaction on Friday, August 5th. The stock was sold at an average price of $12.40, for a total transaction of $173,600.00. Following the completion of the transaction, the insider now directly owns 189,269 shares of the company’s stock, valued at approximately $2,346,935.60. The disclosure for this sale can be found here. 3.90% of the stock is currently owned by corporate insiders.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Want to see what other hedge funds are holding ELGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endologix Inc. (NASDAQ:ELGX).
Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.